753 related articles for article (PubMed ID: 16669964)
1. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Goldstein JL; Lowry SC; Lanza FL; Schwartz HI; Dodge WE
Aliment Pharmacol Ther; 2006 May; 23(10):1489-98. PubMed ID: 16669964
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
5. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.
Goldstein JL; Aisenberg J; Zakko SF; Berger MF; Dodge WE
Dig Dis Sci; 2008 Mar; 53(3):647-56. PubMed ID: 17676393
[TBL] [Abstract][Full Text] [Related]
7. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled study of the effects of naproxen, aspirin, celecoxib or clopidogrel on gastroduodenal mucosal healing.
Dikman A; Sanyal S; VON Althann C; Whitson M; Desai J; Bodian C; Brooks A; Bamji N; Cohen L; Miller K; Aisenberg J
Aliment Pharmacol Ther; 2009 Apr; 29(7):781-91. PubMed ID: 19183162
[TBL] [Abstract][Full Text] [Related]
9. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
10. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
Bianchi Porro G; Lazzaroni M; Petrillo M
Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
[TBL] [Abstract][Full Text] [Related]
13. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
15. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
Rahme E; Nedjar H; Bizzi A; Morin S
Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G;
Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
[TBL] [Abstract][Full Text] [Related]
17. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
20. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
